Abstract :

Migraine is a prevalent headache ailment while Episodic migraine (EM) is a paroxysmal disorder in which attacks occur at random, frequently in clusters lasting several days or weeks. The World Health Organization (WHO) currently ranks migraine as the 19th cause of years spent with a disability. The diagnosis of EM is based on clinical history and the exclusion of other headache disorders because there are no biological markers for migraine. Preventive migraine therapy is beneficial in individuals who have frequent migraine episodes, hindered daily activities, failure of acute pain management, debilitating aura, and limits in the use of acute treatment. Its goal is to reduce headache frequency and severity, enhance responsiveness to acute migraine therapy, and improve quality of patient’s life.

---

Keywords :

Acute migraine, Drugs, Episodic migraine, Therapeutic interventions, Tiptans.

---

References :

1. Buse DC, Loder EW, Gorman JA, Stewart WF, Reed ML, Fanning KM, et al. Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: results of the American migraine prevalence and prevention (AMPP) study. Headache. 2013;53:1278–99.
2. Stewart WF, Roy J, Lipton RB. Migraine prevalence, socioeconomic status, and social causation. Neurology. 2013;81(11):948–55.
3. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004, 24 Suppl 1:9–160.
4. Ranganathan LN, Ramamurthy G, Kanthimathinathan S. Preventive Oral Treatment of Episodic Migraine: An Overview. Neurol India 2021;69, Suppl S1:51-8.
5. Silberstein SD, Goadsby P. Migraine: Preventative treatment. Cephalalgia. 2002;22:491–512.
6. Holm JE, Bury L, Suda KT. The relationship between stress, headache, and the menstrual cycle in young female migraineurs. Headache. 1996;36(9):531–7.
7. Kelman L. The triggers or precipitants of the acute migraine attack. Cephalalgia. 2007;27(5):394–402.
8. Afridi SK, Kaube H, Goadsby PJ. Glyceryl trinitrate triggers premonitory symptoms in migraineurs. Pain. 2004;110(3):675–80.
9. Antonova M, Wienecke T, Olesen J, Ashina M. Prostaglandin E(2) induces immediate migraine-like attack in migraine patients without aura. Cephalalgia. 2012;32(11):822–33.
10. Monro J, Brostoff J, Carini C, Zilkha K. Food allergy in migraine. Study of dietary exclusion and RAST. Lancet. 1980;2(8184):1–4.
11. Torelli P, Evangelista A, Bini A, Castellini P, Lambru G, Manzoni GC. Fasting headache: a review of the literature and new hypotheses. Headache. 2009;49(5):744–52.
12. Turner DP, Smitherman TA, Penzien DB, Porter JA, Martin VT, Houle TT. Nighttime snacking, stress, and migraine activity. J Clin Neurosci. 2014;21(4):638–43.
13. Garcia-Martin E, Martinez C, Serrador M, onso-Navarro H, Navacerrada F, Agundez JA, et al. Alcohol dehydrogenase 2 genotype and risk for migraine. Headache. 2010;50(1):85–91.
14. Henderson WR, Raskin NH. “Hot dog” headache: individual susceptibility to nitrite. Lancet. 1972;2:1162–3.
15. Lassen LH, Christiansen I, Iversen HK, Jansen-Olesen I, Olesen J. The effect of nitric oxide synthase inhibition on histamine induced headache and arterial dilatation in migraineurs. Cephalalgia. 2003;23(9):877–86.
16. Karli N, Baykan B, Ertas M, Zarifoglu M, Siva A, Saip S, et al. Impact of sex hormonal changes on tension-type headache and migraine: a cross-sectional population-based survey in 2,600 women. J Headache Pain. 2012;13(7):557–65.
17. Loder EW. Menstrual migraine: pathophysiology, diagnosis, and impact. Headache. 2006;46(Suppl 2):S55–60.
18. Meng ID, Cao L. From migraine to chronic daily headache: the biological basis of headache transformation. Headache. 2007;47(8):1251–8.
19. Brennan KC, Bates EA, Shapiro RE, Zyuzin J, Hallows WC, Huang Y, et al. Casein kinase idelta mutations in familial migraine and advanced sleep phase. SciTranslMed. 2013;5(183):183ra56.
20. Pringsheim T, Davenport WJ, Becker WJ. Prophylaxis of migraine headache. CMAJ 2010;182:E269-76.
21. Rapoport A. Acute and prophylactic treatments for migraine: Present and future. Neurol Sci. 2008;29:S110–22.
22. Rabbie R, Derry S, Moore RA, McQuay HJ. Ibuprofen with and without an anti-emetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2010;10:CD008039.
23. Silberstein S. Practice parameter: Evidence based guidelines for migraine headache (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 2000;55:754–63.
24. Habib, Safia & Alam, Mudassir & Mustafa, Mohd & Verma, Abhishek Kumar. (2021). Role of Beta-Blockers as an Effective Cardio protective Agents, an insight in to Tackling with Cardiovascular Diseases (CVDs) and Hypertension. 3. 27-35.
25. Koella WP. CNS-related (side-) effects of beta-blockers with special reference to mechanisms of action. Eur J Clin Pharmacol 1985;28(Suppl):55-63.
26. Fernández-de-las-Peñas C, Chaitow L, Schoenen J. Multidisciplinary Management of Migraine: Pharmacological, Manual, and Other Therapies. 1st ed.. Burlington (MA). Jones & Bartlett Publishers; 2012.
27. Law MR, Morris JK, Wald NJ. Calcium channel blockers and headache. Br J Clin Pharmacol. 2007 Feb;63(2):157-8. doi: 10.1111/j.1365-2125.2006.02751.x. Epub 2006 Aug 30. PMID: 16939526; PMCID: PMC2000571.
28. Xu XM, Liu Y, Dong MX, Zou DZ, Wei YD. Tricyclic antidepressants for preventing migraine in adults. Medicine (Baltimore). 2017 Jun;96(22):e6989. doi: 10.1097/MD.0000000000006989. PMID: 28562550; PMCID: PMC5459715.
29. Solomon GD, Steel JG, Spaccavento LJ. Verapamil prophylaxis of migraine. A double-blind, placebo-controlled study. JAMA 1983;250:2500-2.
30. Moja, L., Cusi, C., Sterzi, R., & Canepari, C. (2005). Selective serotonin re‐uptake inhibitors (SSRIs) for preventing migraine and tension‐type headaches. Cochrane Database of Systematic Reviews, (3).
31. Ozyalcin S, Talu G, Kiziltan E, Yucel B, Ertas M, Disci R. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache. 2005;45:144–52.
32. Rothrock JF. Clinical studies of valproate for migraine prophylaxis. Cephalalgia.
33. Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: A triple-blind, placebo-controlled crossover study. Neurology 1994;44:647-51.
34. Steiner TJ, Findley LJ, Yuen AW. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura.
35. Silberstein SD, Neto W, Schmitt J, Jacobs D, MIGR-001 Study Group. Topiramate in migraine prevention: Results of a large controlled trial. Arch Neurol 2004;61:490-5.
36. Diener HC, Tfelt-Hansen P, Dahlöf C, Láinez MJ, Sandrini G, Wang SJ, et al. Topiramate in migraine prophylaxis–results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004;251:943-50.
37. Lampl C, Katsarava Z, Diener H, et al Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura Journal of Neurology, Neurosurgery & Psychiatry 2005;76:1730-1732.
38. Linde M. Migraine: A review and future directions for treatment. Acta Neurol Scand. 2006;114:71–83.
39. Gladstone JP, Dodick DWAcute Migraine: Which Triptan? Practical Neurology 2004;4:6-19.
40. Alam, M., Abbas, K., Harina, & Verma, A.K. (2021). “An Insight into Neurodegenerative Disorders, their therapeutic approaches and drugs available for tackling with Neurodegeneration: A Review”.
41. Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev. 2004;1:CD002286.
42. Namazi N, Heshmati J, Tarighat-Esfanjani A. Supplementation with Riboflavin (Vitamin B2) for Migraine Prophylaxis in Adults and Children: A Review. Int J Vitam Nutr Res. 2015;85(1-2):79-87. doi: 10.1024/0300-9831/a000225. PMID: 26780280.